ClinicalTrials.gg
CompletedNCT04039503SURPASS-5Updated Jan 12, 2022Results posted

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

A Phase 3 interventional study of Tirzepatide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 48 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-12.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
475
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
11th of 43
475 · median 160
Started
2019
with 7 others
Phase 3
17 of 43
1 open now
Registered
12th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 8 that started in 2019, is one of 17 in phase 3, and was the 12th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin. Participants will administer tirzepatide or placebo along with their previous glucose lowering medications. The study will last approximately 47 weeks and may include about 23 visits.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • glucose-dependent insulinotropic polypeptide (GIP)
  • glucagon-like peptide-1 (GLP-1)
  • GIP/GLP-1 dual receptor agonist
  • T2DM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have been diagnosed with type 2 diabetes mellitus (T2DM) and have been treated with insulin glargine (U100), once daily with or without metformin ≥3 months prior to screening visit.
  • Have between ≥7.0% and ≤10.5%.
  • Have a stable weight (± 5%) for at least 3 months before screening.
  • Have a (BMI) ≥23 kilograms per meter squared (kg/m²) at screening.

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus.
  • Have had chronic or acute pancreatitis any time prior to study entry.
  • Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment.
  • Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss.
  • Have an estimated \<30 mL/minute/1.73 m² [for participants on metformin, estimated glomerular filtration rate \<45 mL/min/1.73 m2 (or lower than the country-specific threshold for using the protocol-required dose of metformin per local label)]
  • Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months.
  • Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2.
  • Have been taking weight loss drugs, including over-the-counter medications during the last 3 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
475 participants (actual)

Study arms

  • Experimental
    5 mg Tirzepatide

    5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.

    Drug: Tirzepatide

  • Experimental
    10 mg Tirzepatide

    10 mg tirzepatide administered SC once a week.

    Drug: Tirzepatide

  • Experimental
    15 mg Tirzepatide

    15 mg tirzepatide administered SC once a week.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Placebo administered SC once a week.

    Drug: Placebo

Interventions

  • Administered SC as add-on to the pre-trial background medication.

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC as add-on to the pre-trial background medication.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 40

Secondary outcomes

  1. Change From Baseline in HbA1c (5 mg)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 40

  2. Change From Baseline in Body Weight

    Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline HbA1c Group (\<= 8.0%, \>8.0%) + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 40

  3. Percentage of Participants Achieving an HbA1c Target Value of <7%

    Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A.HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Week 40

  4. Change From Baseline in Fasting Serum Glucose

    Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. LS Mean was determined by MMRM model with Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<= 8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 40

  5. Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values

    The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Postmeal, Midday Premeal, Midday 2-hour Postmeal, Evening Premeal, Evening 2-hour Postmeal and Bedtime. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline HbA1c Group (\<= 8.0%, \>8.0%) + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment (Type III sum of squares).

    Time frame: Baseline, Week 40

  6. Percentage of Participants Who Achieved Weight Loss ≥5%

    Percentage of Participants who Achieved Weight Loss ≥5%.

    Time frame: Week 40

  7. Percentage Change From Baseline in Daily Mean Insulin Glargine Dose

    LS mean was calculated using MMRM model with log (Baseline) + Baseline Metformin Use (Yes, No) + Pooled Country + Baseline HbA1c Group (\<= 8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 40

  8. Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 Millimole/Liter (mmol/L)] or Severe Hypoglycemia

    The hypoglycemia events were defined by participant reported events with blood glucose \<54mg/dL) (\<3.0 mmol/L\] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of postbaseline hypoglycemia was estimated by negative binomial model: number of episodes = Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<= 8.0%, \>8.0%) + Treatment, with log (exposure in days/365.25) as an offset variable.

    Time frame: Baseline through Safety Follow-Up (Up to Week 44)

  9. Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide

    AUC is a combined measure obtained from Week 7, 15, 23 and 39 and a single averaged measure of AUC was reported.

    Time frame: Week 7, 15, 23 and 39 post dose

  10. Percentage of Participants Achieving an HbA1c Target Value of <5.7%

    Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Week 40

07

Results

Posted Jan 12, 2022

Participant flow

Participant flow — Overall Study
Milestone5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Started116119120120
Received at least one dose of study drug116119120120
Completed109115110117
Not completed74103
Withdrew: Adverse event3020
Withdrew: Lost to follow-up0010
Withdrew: Protocol violation0121
Withdrew: Withdrawal by subject4352

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
Percentage of HbA1c10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)-2.59 ± 0.081-2.59 ± 0.083-0.93 ± 0.079
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.66 · 95% CI -1.88 to -1.43
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.65 · 95% CI -1.88 to -1.43
SecondaryChange From Baseline in HbA1c (5 mg)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in HbA1c (5 mg)
Percentage of HbA1c5 mg TirzepatidePlacebo
Change From Baseline in HbA1c (5 mg)-2.23 ± 0.081-0.93 ± 0.079
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.30 · 95% CI -1.52 to -1.07
SecondaryChange From Baseline in Body Weight

Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline HbA1c Group (\<= 8.0%, \>8.0%) + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Kilograms (kg)
Change From Baseline in Body Weight
Kilograms (kg)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Body Weight-6.2 ± 0.58-8.2 ± 0.58-10.9 ± 0.591.7 ± 0.57
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -7.8 · 95% CI -9.4 to -6.3
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -9.9 · 95% CI -11.5 to -8.3
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -12.6 · 95% CI -14.2 to -11.0
SecondaryPercentage of Participants Achieving an HbA1c Target Value of <7%

Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A.HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Week 40
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an HbA1c Target Value of <7%
Percentage of Participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Achieving an HbA1c Target Value of <7%93.0497.3594.0233.90
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 37.77 · 95% CI 15.23 to 93.70
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 100.07 · 95% CI 30.02 to 333.62
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 43.31 · 95% CI 16.92 to 110.83
SecondaryChange From Baseline in Fasting Serum Glucose

Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. LS Mean was determined by MMRM model with Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<= 8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · milligram per Deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose
milligram per Deciliter (mg/dL)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Change From Baseline in Fasting Serum Glucose-61.4 ± 2.55-67.9 ± 2.55-67.7 ± 2.64-38.9 ± 2.49
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -22.5 · 95% CI -29.5 to -15.4
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -29.0 · 95% CI -36.0 to -22.0
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -28.8 · 95% CI -35.9 to -21.6
SecondaryMean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values

The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Postmeal, Midday Premeal, Midday 2-hour Postmeal, Evening Premeal, Evening 2-hour Postmeal and Bedtime. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline HbA1c Group (\<= 8.0%, \>8.0%) + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment (Type III sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · mg/dL
Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values
mg/dL5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values-67.1 ± 2.05-71.7 ± 2.04-73.7 ± 2.10-39.4 ± 2.07
SecondaryPercentage of Participants Who Achieved Weight Loss ≥5%

Percentage of Participants who Achieved Weight Loss ≥5%.

Time frame:
Week 40
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Weight Loss ≥5%
Percentage of Participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieved Weight Loss ≥5%53.9164.6084.625.93
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 17.15 · 95% CI 7.55 to 38.93
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 27.24 · 95% CI 11.87 to 62.55
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 79.61 · 95% CI 32.76 to 193.44
SecondaryPercentage Change From Baseline in Daily Mean Insulin Glargine Dose

LS mean was calculated using MMRM model with log (Baseline) + Baseline Metformin Use (Yes, No) + Pooled Country + Baseline HbA1c Group (\<= 8.0%, \>8.0%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · International Units (IU)
Percentage Change From Baseline in Daily Mean Insulin Glargine Dose
International Units (IU)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage Change From Baseline in Daily Mean Insulin Glargine Dose13.0 ± 7.348.1 ± 7.03-11.4 ± 5.8575.0 ± 11.11
Statistical analysis
  • 5 mg Tirzepatide vs 10 mg Tirzepatide · Estimate difference: -35.4 · 95% CI -46.0 to -22.8
  • 10 mg Tirzepatide vs Placebo · Estimate difference: -38.2 · 95% CI -48.3 to -26.1
  • 15 mg Tirzepatide vs Placebo · Estimate difference: -49.3 · 95% CI -57.7 to -39.4
SecondaryRate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 Millimole/Liter (mmol/L)] or Severe Hypoglycemia

The hypoglycemia events were defined by participant reported events with blood glucose \<54mg/dL) (\<3.0 mmol/L\] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of postbaseline hypoglycemia was estimated by negative binomial model: number of episodes = Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (\<= 8.0%, \>8.0%) + Treatment, with log (exposure in days/365.25) as an offset variable.

Time frame:
Baseline through Safety Follow-Up (Up to Week 44)
Reported as:
Mean · Episodes/participant/365.25 days
Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 Millimole/Liter (mmol/L)] or Severe Hypoglycemia
Episodes/participant/365.25 days5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 Millimole/Liter (mmol/L)] or Severe Hypoglycemia0.49 ± 0.1410.66 ± 0.1690.38 ± 0.0990.51 ± 0.149
SecondaryPharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide

AUC is a combined measure obtained from Week 7, 15, 23 and 39 and a single averaged measure of AUC was reported.

Time frame:
Week 7, 15, 23 and 39 post dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide
nanogram*hour per milliliter (ng*h/mL)5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC) of Tirzepatide79700 ± 24.5164000 ± 26.7246000 ± 26.4
SecondaryPercentage of Participants Achieving an HbA1c Target Value of <5.7%

Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Week 40
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an HbA1c Target Value of <5.7%
Percentage of Participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Achieving an HbA1c Target Value of <5.7%26.0947.7962.392.54
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 12.22 · 95% CI 3.93 to 38.00
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 32.36 · 95% CI 10.52 to 99.49
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 56.26 · 95% CI 18.27 to 173.26

Adverse events

Collected over Baseline, 17 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide0/116 (0%)9/116 (7.8%)52/116 (44.8%)
10 mg Tirzepatide0/119 (0%)13/119 (10.9%)60/119 (50.4%)
15 mg Tirzepatide0/120 (0%)9/120 (7.5%)67/120 (55.8%)
Placebo0/120 (0%)10/120 (8.3%)58/120 (48.3%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
Cardiac failureCardiac disorders3/1161/1190/1200/120
Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/551/470/550/54
Coronary artery diseaseCardiac disorders0/1160/1192/1200/120
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1160/1192/1200/120
Atrial fibrillationCardiac disorders1/1160/1190/1200/120
FaecalomaGastrointestinal disorders1/1160/1190/1200/120
AstheniaGeneral disorders1/1160/1190/1200/120
Coronavirus infectionInfections and infestations1/1160/1190/1200/120
GastroenteritisInfections and infestations1/1160/1190/1200/120
Papillary renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1160/1190/1200/120
Most frequent other events
Showing 10 of 14
Most frequent other events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlacebo
DiarrhoeaGastrointestinal disorders14/11615/11925/12012/120
NasopharyngitisInfections and infestations18/1168/11915/12023/120
NauseaGastrointestinal disorders15/11621/11922/1203/120
Decreased appetiteMetabolism and nutrition disorders8/11615/11917/1202/120
HyperglycaemiaMetabolism and nutrition disorders2/1160/1191/12016/120
VomitingGastrointestinal disorders8/1169/11915/1203/120
DyspepsiaGastrointestinal disorders8/11610/1196/1202/120
Lipase increasedInvestigations4/1162/11910/1202/120
ConstipationGastrointestinal disorders7/1168/1198/1202/120
EructationGastrointestinal disorders6/1164/1197/1201/120

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Mean61.50 ± 9.8160.40 ± 10.2460.50 ± 9.9260.00 ± 9.6360.60 ± 9.88
Sex: Female, Male
Sex: Female, Male(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Female55475554211
Male61726566264
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Hispanic or Latino485522
Not Hispanic or Latino94959398380
Unknown or Not Reported1816221773
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
American Indian or Alaska Native01102
Asian2021222285
Native Hawaiian or Other Pacific Islander00000
Black or African American12306
White95949497380
More than one race01012
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Czechia2424232394
Germany32323332129
Japan1921202282
Poland8910936
Puerto Rico261312
Slovakia878831
Spain1315151457
United States10510934
Hemoglobin A1c
Hemoglobin A1c(Percentage of HbA1c)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Mean8.30 ± 0.888.36 ± 0.838.23 ± 0.868.37 ± 0.848.31 ± 0.85
08

Study locations

48 sites
  • Valley Endocrine, Fresno
    Fresno, California 93720, United States
  • Sun Coast Clinical Research, Inc
    New Port Richey, Florida 34652, United States
  • Southern New Hampshire Diabetes and Endocrinology
    Nashua, New Hampshire 03063, United States
  • Manhattan Medical Research
    New York, New York 10016, United States
  • Intend Research
    Norman, Oklahoma 73069, United States
  • Milan Kvapil s.r.o.
    Pribram, Středočeský Kraj 26201, Czechia
  • Diacentrum Brandys n.L. s.r.o.
    Brandys Nad Labem-Stara Bolesl, 25001, Czechia
  • Diabetologicka ordinace pro dospele
    Krnov, 79401, Czechia
  • Diahelp s.r.o., Interni a diabetologicka ambulance
    Pardubice, 53002, Czechia
  • Lekarna Dr. Max
    Praha 1, 11000, Czechia
  • Milan Kvapil s.r.o.
    Praha 4, 149 00, Czechia
  • RESTRIAL s.r.o.
    Praha 8, 181 00, Czechia
  • Praxis Dr. Jörg Lüdemann
    Falkensee, Brandenburg 14612, Germany
  • Arztpraxis Dr. Cornelia Marck
    Pohlheim, Hessen 35415, Germany
  • InnoDiab Forschung GmbH
    Essen, Nordrhein-Westfalen 45136, Germany
  • Institut für Diabetesforschung Münster GmbH
    Münster, Nordrhein-Westfalen 48145, Germany
  • Praxis Dr. Kempe - Dr. Stemler
    Ludwigshafen am Rhein, Rheinland-Pfalz 67059, Germany
  • Schwerpunktpraxis Diabetes
    Saint Ingbert-Oberwürzbach, Saarland 66386, Germany
  • SMO.MD GmbH
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • RED-Institut GmbH
    Oldenburg in Holstein, Schleswig Holstein 23758, Germany
  • Diabetologische Schwerpunktpraxis B. Scholz/Dr. B. Paschen
    Hamburg, 21073, Germany
  • Gemeinschaftspraxis für innere Medizin und Diabetologie
    Hamburg, 22607, Germany
  • Kashiwa hospital
    Kashiwa, Chiba 277-0825, Japan
  • Manda Hospital
    Sapporo, Hokkaido 060-0062, Japan
  • Takai Naika Clinic
    Kamakura, Kanagawa 247-0056, Japan
  • Takatsuki Red Cross Hospital
    Takatsuki, Osaka 569-1096, Japan
  • Tokyo-Eki Center-building Clinic
    Chuo-ku, Tokyo 103-0027, Japan
  • Tokyo Center Clinic
    Chuo-ku, Tokyo 103-0028, Japan
  • Tokyo Clinical Trial Centre Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • The Institute for Adult Diseases, Asahi Life Foundation
    Chuou-ku, Tokyo 1030002, Japan
  • Sato Naika Clinic
    Ota-ku, Tokyo 143-0015, Japan
  • Jinnouchi Hospital
    Kumamoto, 862-0976, Japan
  • Centrum Medyczne AMED
    Warszawa, Mazowieckie 01-518, Poland
  • NZOZ ZDROWIE Osteo-Medic
    Bialystok, Podlaskie 15-351, Poland
  • Centrum Badan Klinicznych, PI House
    Gdansk, Pomorskie 80-546, Poland
  • NZOZ Przychodnia Specjalistyczna MEDICA
    Lublin, 20-538, Poland
  • Centro de Endocrinologia y Nutricion del Turabo
    Caguas, 00725, Puerto Rico
  • Manati Center for Clinical Research Inc
    Manati, 00674, Puerto Rico
  • Ambulancia vnútorného lekárstva Hnúša (Diabetes care)
    Hnusta, 98101, Slovakia
  • Sin Azucar
    Malacky, 901 01, Slovakia
  • Dia-Clarus.s.r.o.
    Prievidza, 971 01, Slovakia
  • JAL
    Trnava, 917 01, Slovakia
  • Medivasa, s.r.o.
    Zilina, 01001, Slovakia
  • Hospital Clinico Universitario Virgen de la Victoria
    Malaga, Andalucia 29010, Spain
  • Hospital de la Ribera
    Alcira, Valencia 46600, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41009, Spain
  • Hospital Infanta Luisa
    Sevilla, 41010, Spain
  • Hospital Universitari i Politecnic La Fe-ENDO
    València, 46026, Spain
09

References and documents

Publications

  • Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022 Mar;28(3):591-598. doi: 10.1038/s41591-022-01707-4. Epub 2022 Feb 24. PubMed 35210595 ↗
  • Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodriguez A. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078. PubMed 35133415 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Dec 2020, 15 months.

Results were first posted in Jan 2022, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 15 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2019
First posted
Jul 31, 2019
StartActual
Aug 30, 2019
Primary completionActual
Dec 22, 2020
CompletionActual
Jan 13, 2021
Results first posted
Jan 12, 2022
Last update
Jan 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04039503
Responsible party
Sponsor
First posted
Jul 31, 2019
Start date
Aug 30, 2019
Primary completion
Dec 22, 2020
Completion
Jan 13, 2021
Results posted
Jan 12, 2022
Last update
Jan 12, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion